Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma
Status:
Suspended
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This study will be a multi-center, open-label, Phase 2 study where newly diagnosed Multiple
Myeloma requiring systemic chemotherapy will be eligible for enrollment. A total of 55
subjects will be enrolled. Time to progression or death will be calculated from the date of
first treatment on protocol until the date of disease progression or death from any cause.
Patients can expect to participate between 12-24 cycles. The primary endpoint will be the
rate of response by next generation gene sequencing at the end of 8 cycles among
non-transplant candidates and transplant candidates who agreed to defer transplant.
Phase:
Phase 2
Details
Lead Sponsor:
University of Chicago
Collaborators:
Amgen Bristol-Myers Squibb Multiple Myeloma Research Foundation